Citicoline Dosage: What the Trials Actually Used

Citicoline trials span 250–2,000 mg per day, but the range splits cleanly by population. Healthy-adult and Cognizin studies cluster at 250–500 mg/day; clinical work in age-related and vascular cognitive impairment used 500–1,000 mg/day for 9 to 12 months or longer.¹ More is not better here — the Alzheimer’s Drug Discovery Foundation notes that in healthy people the lower end, around 250 mg, may be more effective than higher doses, and one trial found participants with high baseline performance did slightly worse.

The closest thing we can honestly point at

Neuro-Thrive

It does not contain citicoline. It uses a different choline donor — alpha-GPC at 150 mg — and it is on our list because it publishes every dose on its panel, including bacopa monnieri at 300 mg standardized to 50% bacosides. The caveats travel with it: its PQQ is 10 mg where the cognitive trial that ingredient is sold on used 20 mg/day, and a Korean national cohort of more than 12 million adults associated alpha-GPC use with roughly 43% higher 10-year stroke risk. If you specifically want citicoline, this is not that product, and we would rather say so than pretend otherwise.

We earn a commission if you buy through this link. It costs you nothing extra and it does not change what we write.

Full Neuro-Thrive review: doses, price, guarantee →

Check the current price →

Written by the Fog & Clarity editorial team · Published 4 August 2026 · Last updated 4 August 2026

The doses that appear in trials

Citicoline — cytidine 5′-diphosphocholine, sold as Cognizin in its branded form and prescribed as Somazina or Ceraxon in parts of Europe and Latin America — has a wider published dose range than almost anything else in this category. The range is wide because two different literatures are stacked on top of each other: a supplement literature in healthy people and a clinical literature in impaired ones.

Source	Population	Daily dose	Duration	Outcome
Full published range	Mixed	250–2,000 mg	Varies	Spans supplement and clinical use
Healthy-adult and Cognizin trials	Healthy adults	250–500 mg	Short-term	Small acute attention and processing-speed effects
Clinical work in cognitive impairment	Age-related and vascular impairment	500–1,000 mg	9–12+ months	Modest benefit reported
ADDF observation on healthy people	Healthy adults	~250 mg	—	Lower may beat higher
EFSA ceiling cited by ADDF	Middle-aged and elderly adults	500 mg supplement; 1,000 mg medical food	—	A maximum, not an efficacy dose

Alvarez and colleagues reported memory improvement in elderly participants, and that trial is one of the reasons citicoline is taken seriously at all.² An EFSA Article 13(5) opinion on citicoline and memory was published in 2024;³ we have not been able to read its full text, so we are not characterizing its conclusion in either direction. When we can, this page gets updated.

What that means for a healthy adult

Evidence tier for citicoline on this site: Moderate — and the population it is moderate in is probably not you.

Citicoline is marketed as a universal focus-and-memory agent. What the evidence supports is narrower: modest benefits in age-related and vascular cognitive impairment, plus small acute effects on attention and processing speed concentrated in lower-performing individuals.¹ That last qualifier is the one the marketing drops. If your attention is already unimpaired, the trial data does not describe you, and one trial found high-baseline participants slipped slightly rather than improving.

There is a larger negative result that almost never appears in supplement copy. Citicoline’s most rigorous testing was in acute ischemic stroke, in large trials, and it did not show benefit relative to current standard of care.¹ That is not a disqualification of the supplement dose — different population, different question — but a compound that failed its best-powered test deserves to be described with that fact attached.

For scale, the only large, randomized, multi-year, replicated positive cognitive result anywhere in this field came from a plain daily multivitamin-mineral: 2,262 participants on Centrum Silver for three years in COSMOS-Mind showed better global cognition than placebo, and a meta-analysis across the three COSMOS cognitive sub-studies supported a modest overall benefit.⁹¹⁰ That result is also small. It is still the biggest one there is. We put the comparison side by side on the multivitamin page.

Why the dose on your bottle is probably different

Citicoline suffers less from underdosing than most botanicals, because 250 mg is cheap enough to include honestly and because Cognizin’s licensing encourages naming it. The gaps show up in three other places.

Blend arithmetic. A multi-ingredient “focus complex” that lists a 400 mg total cannot contain 250 mg of citicoline plus anything meaningful. The math is the tell, and it is the reason proprietary blends exist as a labeling device.
Choline source substitution. Choline bitartrate, alpha-GPC and citicoline are three different molecules with three different literatures. A label that says “choline complex” is not telling you which one you bought.
Serving size. “500 mg” printed above “serving size: 2 capsules” is 250 mg in your hand. Read the serving line first.

Among the formulas we are willing to link, Neuro-Thrive is the one that publishes a complete dose panel — and it is worth saying plainly that its choline donor is alpha-GPC at 150 mg, not citicoline, so it is not a substitute if citicoline is what you were looking for. Its own caveats stand: 10 mg of PQQ against the 20 mg/day used in the trial that ingredient is sold on,⁸ and the alpha-GPC stroke signal from the Korean cohort.⁵ Disclosure is what lets you check any of that. It is not the same as a recommendation.

Third-party certification answers a different question again — what NSF, USP and Informed Choice actually certify is identity and contamination, not efficacy, and not dose adequacy.

Form matters more than milligrams here

Citicoline delivers both choline and cytidine, which is the mechanistic argument for preferring it over plain choline salts. Alpha-GPC is the other pharmaceutical-grade choline donor in wide use, and its efficacy evidence sits in a different place entirely: a 2023 systematic review and meta-analysis of 8 studies and 861 participants found an MMSE mean difference of 3.50 (95% CI 0.36–6.63) for monotherapy versus placebo — in clinical dementia populations, mostly alongside donepezil.⁴ Neither compound has convincing healthy-adult memory data.

The practical difference is the safety file. Citicoline is among the best-tolerated agents in this reference, with no serious safety issues reported including in use up to three years.¹ Alpha-GPC carries a large observational stroke signal with a dose-response gradient, alongside a separate Korean analysis suggesting delayed dementia conversion in users — a genuinely conflicted literature.⁵⁶⁷ If you are choosing between the two on risk rather than on effect size, that asymmetry is the whole argument.

Safety ceiling and who should not take this

Reported adverse effects are mild and mostly gastrointestinal: stomach upset, headache, insomnia. The EFSA figure cited by ADDF — 500 mg/day for supplements, 1,000 mg/day for medical foods in middle-aged and elderly adults — is the most useful published ceiling, and it is a regulatory maximum rather than a target.¹

⚠️ Talk to your prescriber first

Citicoline has a possible, poorly characterized interaction with levodopa and other Parkinson’s medications — poorly characterized is not the same as absent, and this is a category where dose timing matters clinically. It is also theoretically additive with cholinergic drugs, so it should not be stacked with a cholinesterase inhibitor (donepezil, rivastigmine, galantamine) without clinical supervision. If you take prescription medication of any kind, clear it with the person who prescribed it.

If you are on an antidepressant, our compound-by-compound interaction guide separates the documented concerns from the theoretical ones. And if a surgery is scheduled, the general rule for supplements — stop well before the date and tell the anesthetist — applies regardless of how benign the compound looks.

What we don’t know

Whether 250 mg genuinely beats 500 mg in healthy adults. The ADDF observation points that way. It is an observation across a literature, not the result of a head-to-head dose-ranging trial.
Why high performers did worse in one trial. An inverted-U dose-response is a plausible explanation and an untested one. Nobody has replicated the finding either.
What the 2024 EFSA opinion concluded. We could not retrieve the full text. Until we can, this page treats it as unread rather than as support.
Whether the impaired-population benefit extends downward. “Lower-performing” in an attention study is not the same as “impaired,” and the boundary between them has never been mapped.

What would change our mind

A pre-registered dose-ranging RCT in healthy adults — 250 mg versus 500 mg versus placebo, at least 300 participants, at least six months, stratified by baseline cognitive performance so the inverted-U question gets answered directly. If that trial found a benefit at 250 mg in ordinary healthy adults and not just in the lowest-performing stratum, citicoline would move up the tier list on this site. If it confirmed that high performers do slightly worse, we would write that as the headline, because it is the more useful finding.

Frequently asked questions

Is 250 mg or 500 mg of citicoline better?

For a healthy adult, 250 mg is the more defensible choice. ADDF’s read of the literature is that lower doses may be more effective than higher ones in healthy people, and 500 mg is also the EFSA supplement ceiling for middle-aged and elderly adults. The 500–1,000 mg band belongs to clinical trials in cognitive impairment, not to general use.

Is Cognizin different from generic citicoline?

Cognizin is a branded citicoline from Kyowa Hakko, and most healthy-adult trials used it. That gives you a characterized material with a known trial dossier at 250–500 mg. It does not make the molecule different, and no head-to-head trial has shown branded citicoline outperforming generic citicoline at the same dose.

How long does citicoline take to work?

The attention and processing-speed effects reported in healthy adults are acute, appearing within hours in the trials that found them. The clinical evidence in cognitive impairment runs 9 to 12 months or more. Those are two different claims on two different timescales, and a product page that merges them is telling you about neither.

Can I take citicoline with alpha-GPC?

There is no trial of the combination, and stacking two cholinergic agents raises the theoretical interaction profile of both — particularly against cholinesterase inhibitors. Given the alpha-GPC stroke cohort, we would not describe the pair as a low-risk stack, and anyone with cerebrovascular history should treat it as a clinician question.

Does citicoline help with brain fog?

Not on the evidence here. There is no trial of citicoline for brain fog as people use the term, and the closest analogue — acute attention effects in lower-performing individuals — is a long way from a symptom with dozens of possible causes. If fog is persistent, the more useful first step is working through the medical explanations.

Sources

These statements have not been evaluated by the Food and Drug Administration. Nothing here is intended to diagnose, treat, cure or prevent any disease.

This article is information, not medical advice. Talk to a doctor or pharmacist about your own situation, especially if you take prescription medication.